Repros Therapeutics Inc. and Efficacy Capital Announce Standstill Agreement

2008-01-10
THE WOODLANDS, Texas--(BUSINESS WIRE)--Repros Therapeutics Inc. (NasdaqGM:RPRX) announced today that the Board of Directors has approved an amendment to its Shareholder Rights Plan that permits the Company's largest shareholder, Efficacy Capital, to purchase up to 33% of the Company's outstanding capital stock on the open market or in potential future purchases directly from Repros. Efficacy currently owns a percentage that is slightly below the current twenty percent (20%) threshold in the Rights Plan. In connection with this Amendment, the Company and Efficacy Capital have entered into a Standstill Agreement containing customary covenants and obligations restricting Efficacy from taking certain actions with respect to its shares. As part of the Standstill Agreement, the Company has agreed to appoint Mark Lappe, Managing Partner at Efficacy, as a director of the Company, should he elect to do so, and to provide Efficacy Capital with observer rights at the Company's board meetings.
适应症
-
靶点
-
药物
-
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。